Key facts
- EnPlusOne Biosciences’s last known valuation is $32.3M (Feb 2025).
- It has raised $21.8M across 1 recorded rounds; the latest was Early Stage VC ($21.8M) in Aug 2022.
- Notable investors include Coatue Management, Harvard University, Breakout Ventures, Northpond Ventures, Wyss Institute at Harvard University.
- EnPlusOne Biosciences has filed 3 Form Ds with the SEC since 2022, most recently Dec 2024 ($12.9M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for EnPlusOne Biosciences
Funding rounds
1 roundsAbout EnPlusOne Biosciences
Developer of a synthesis platform intended to revolutionize the diverse array of nucleotide modifications. The company's platform offers enzymatic-based RNA synthesis to address systemic issues inherent to existing chemical synthesis methods and the expansion of RNA therapeutics has uncovered key issues including scaled production and access to innovative therapeutic modifications, enabling the manufacturing process to deliver therapeutic RNA at a commercial scale sustainably.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2022
- Website
- enplusone.bio/
- Ownership
- Privately Held (backing)
EnPlusOne Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EnPlusOne Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EnPlusOne Biosciences in its N-PORT filings yet. We sweep new filings monthly.